Page 1 of 1

Principles and Practice of Ophthalmology

TABLE 671. Antiviral Agents Used in Anterior Segment Disease Drug Class Spectrum Therapeutic Use Dosage of Activity In Vitro Idoxuridine (IDU, Herplex) Pyrimidine HSV-1, nucleoside HSV-2, VZV, CMV, vaccinia HSV-1 and HSV- HSV keratitis: 0.1% 2 keratitis gtt. q 1 hr by day, q 2 hr at night, or 1 gtt. q 5 min 5, five times daily 2-3 wk Prophylaxis: reduce dose daily by 40-50% HSV-1 and HSVa. HSV or zoster 2 keratitis and keratitis: 3% encephalitis, ointment 5 varicella keratitis times/day, 2-3 wk b. 15 mg/kg/day IV 7-10 days (alternative VZV rx) HSV-1 and HSV- HSV keratitis: 1% gtt. 2 keratitis 9 times/day, 2-3 wk HSV-1 and HSV2 keratitis, retinitis Zoster ophthalmicus, retinitis. EBV efficacy? a. HSV keratitis: 3% ointment 5 times/day 2-3 wk

FDA Approval Status Approved

Vidarabine (ara-A; Vira-A)

Purine HSV-1, nucleoside HSV-2, VZV, CMV, vaccinia

Approved Approved Approved

Trifluorothymidine (TFT, F3T, Viroptic) Acyclovir (Zovirax) (famciclovir, valaciclovir: see text.)

Pyrimidine HSV-1, nucleoside HSV-2, VZV, CMV Purine HSV-1, acyclic HSV-2, sugar VZV, EBV, CMV

Approved

Not approved

b. Acute zoster: 800 mg 5 times/day PO 7-14 day c. HSV infectious keratitis: 400 mg PO t.i.d. 10-21 day d. HSV prophylaxis: 400 mg PO b.i.d.

Approved

Not approved

Not approved

Adapted from Pavan-Langston D, Dunkel EC: Handbook of Ocular Drug Therapy and Ocular Side Effects of Systemic Drugs. Boston, Little, Brown, 1991, p 170. HSV-1, herpes simplex virus type 1, HSV-2, herpes simplex virus type 2; VZV, varicella-zoster virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
Copyright 2000 W.B. Saunders Company

http://127.0.0.1:1080/rami?COMMAND=showFile(t_table.htm)&VOL_ID=11&NODE_I...

8/22/2009